Bain Capital Broadens Its Biotech Reach With $3.3B Deal for Mitsubishi Tanabe Pharma

Bain Capital’s buyout of Mitsubishi Tanabe Pharma brings a company with a drug portfolio and pipeline in areas such as immunology, central nervous system disorders, and metabolic disease. This business is the pharmaceuticals division of Japanese conglomerate Mitsubishi Chemical Group. The post Bain Capital Broadens Its Biotech Reach With $3.3B Deal for Mitsubishi Tanabe Pharma…

Read More

Biocompatible Nanoparticles: Tiny Antennae with Huge Potential for Brain-Computer Interfaces

To bridge the gap between invasive and non-invasive technologies, nanoscale materials, such as biocompatible nanoparticles, provide a promising alternative, allowing us to design materials at the scale of cellular systems and structures. The post Biocompatible Nanoparticles: Tiny Antennae with Huge Potential for Brain-Computer Interfaces appeared first on MedCity News.

Read More